Athira Pharma (ATHA) - EV/EBITDA Multiple
Athira Pharma, Inc. (ATHA) is a biopharmaceutical player developing drugs for nerve cell regeneration in dementia, as clearly demonstrated by the price chart on GURU.Markets, where the EV/EBITDA ratio stands at 0.00. The efficiency of discovering new formulas is enhanced here through robotic screening. The massive unmet demand of millions of patients guarantees the company colossal sales volumes upon confirmation of the therapy's efficacy.
Comprehensive metric breakdowns and analytics for athira.com (ATHA)
- current price and projected stock value:
- market capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Athira Pharma, Inc.|ATHA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Athira Pharma|ATHA - Company Aggregate Indebtedness|Debts to Book Capitalization Athira Pharma Corp|ATHA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Athira Pharma|Quick Liquidity athira.com
- business earnings and investment ratios data:
ATHA - Final Profit|Expected Profit Athira Pharma, Inc.|ATHA - Price to Earnings Ratio|Forward P/E Multiple Athira Pharma, Inc.|ATHA - PEG Multiple|Enterprise Value to EBITDA Ratio Athira Pharma Corp|ATHA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Athira Pharma|ATHA - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months athira.com|ATHA - Earnings per share growth this year|Earnings growth forecast for next year Athira Pharma, Inc.
- company sales and revenue statistics:
Fundamental valuation:Athira ATHA
To minimize risks when building a position, it is essential to evaluate the ratio of Enterprise Value (EV) to earnings before interest, taxes, depreciation, and amortization (EBITDA). The current EV/EBITDA multiple for Athira Pharma, Inc. (ATHA) allows for a comparison between the expansion costs of the drug phosgonimetone and the actual efficiency of assets, determining the resilience of the neuropharmaceutical scaling model to debt load.
Key competitors
EV/EBITDA Multiple BIIB (Biogen Corp)|Business Value to Operating Income Before Depreciation NBIX|Regencell Bioscience - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio axsome.com AXSM|ACADIA Pharmaceuticals Inc. (ACAD) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Xenon Pharmaceuticals Inc. - Business Value to Operating Income Before Depreciation|VKTX (Viking Pharma) - EV/EBITDA Multiple|EV/EBITDA Multiple Supernus Corp|Enterprise Value to EBITDA Ratio CPRX (Catalyst Pharmaceuticals)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harmony Biosciences Holdings, Inc. HRMY|BHVN (Biohaven Ltd) - Company Value to Operating Income Before Depreciation Ratio|Amylyx - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation TRVI (Trevi Corp)|PRAX: EV/EBITDA Multiple|anavex.com (AVXL) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CeriBell|PRTA: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc. (ALEC)|Enterprise Value to EBITDA Ratio Annexon Biosciences Inc. ANNX|EV/EBITDA Multiple OMER (Omeros)|EV/EBITDA Multiple neurogene.com NGNE|ACIU: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VYGR (Voyager Therapeutics Inc)|NMRA: EV/EBITDA Multiple|SCLX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tevogen Bio Holdings|Enterprise Value to Operating Income Before Depreciation ACOG (Alpha Cognition Corp)|EV/EBITDA Multiple CGTX|Enterprise Value to EBITDA Ratio Inhibikase Therapeutics Inc IKT|Cassava - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Assertio Holdings (ASRT)|Coya - EV/EBITDA Multiple|VTGN - EV/EBITDA Multiple|OVID (ovidrx.com) - Enterprise Value to EBITDA Ratio|ABOS: Enterprise Value to Operating Income Before Depreciation Ratio|CRVO (CervoMed Inc) - EV/EBITDA Multiple|ATHE: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple CLNN|EV/EBITDA Multiple pepgen.com (PEPG)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Jupiter Neurosciences JUNS|RLMD: Enterprise Value to Operating Income Before Depreciation|Annovis Bio Corp - EV/EBITDA Multiple|Company Value to EBITDA Grace Therapeutics, Inc.|AIFF (Firefly Neuroscience, Inc) - Enterprise Value to EBITDA Ratio|Klotho Neurosciences (KLTO) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeuroSense Therapeutics Ltd|RVPH: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MetaVia Inc (MTVA)|NRXS - Company Value to EBITDA|EV/EBITDA Multiple HSDT (Helius Medical Technologies)|EV/EBITDA Multiple Passage Bio Inc. PASG|NEUP: Enterprise Value to EBITDA Ratio|Minerva Neurosciences Inc - Enterprise Value to Operating Income Before Depreciation Ratio|ADXN: EV/EBITDA Multiple|Alzamend Neuro - Business Value to Operating Income Before Depreciation|CYCN (Cyclerion Therapeutics Inc.) - EV/EBITDA Multiple|Protagenic (PTIX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ATXI (Avenue Therapeutics, Inc)|EV/EBITDA Multiple BrainStorm Cell Therapeutics Inc. BCLI|CARA: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CHRO (chromocell.com)|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio ITCI (Intra-Cellular Therapies, Inc.)|LBPH (Longboard Pharma) - EV/EBITDA Multiple|MRNS: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple NKGN|EV/EBITDA Multiple neurobopharma.com (NRBO)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|Business Value to Operating Income Before Depreciation SNPX|TRVN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vigil Neuroscience (VIGL) - Enterprise Value to EBITDA Ratio|WENA: EV/EBITDA Multiple|cerevel.com (CERE) - EV/EBITDA Multiple
